These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


116 related items for PubMed ID: 7722242

  • 1. [Vitreoretinal proliferation. I. Clinicopathological aspects].
    Baudouin C, Gastaud P.
    J Fr Ophtalmol; 1994; 17(12):789-99. PubMed ID: 7722242
    [Abstract] [Full Text] [Related]

  • 2. [Vitreoretinal proliferation. II. Pathogenic hypotheses].
    Baudouin C, Gastaud P.
    J Fr Ophtalmol; 1994; 17(12):800-11. PubMed ID: 7722243
    [Abstract] [Full Text] [Related]

  • 3. [Role of macrophages and fibronectin in vitreoretinal proliferation].
    Weller M, Heimann K, Wiedemann P.
    J Fr Ophtalmol; 1988; 11(3):243-7. PubMed ID: 3047202
    [Abstract] [Full Text] [Related]

  • 4. [Clinical risk factors of vitreoretinal proliferations in rhegmatogenous retinal detachment].
    Bonnet M.
    J Fr Ophtalmol; 1994; 17(8-9):530-40. PubMed ID: 7989662
    [Abstract] [Full Text] [Related]

  • 5. EIU in the rat promotes the potential of syngeneic retinal cells injected into the vitreous cavity to induce PVR.
    Behar-Cohen FF, Thillaye-Goldenberg B, de Bizemont T, Savoldelli M, Chauvaud D, de Kozak Y.
    Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3915-24. PubMed ID: 11053294
    [Abstract] [Full Text] [Related]

  • 6. Changes in retinal gene expression in proliferative vitreoretinopathy: glial cell expression of HB-EGF.
    Hollborn M, Tenckhoff S, Jahn K, Iandiev I, Biedermann B, Schnurrbusch UE, Limb GA, Reichenbach A, Wolf S, Wiedemann P, Kohen L, Bringmann A.
    Mol Vis; 2005 Jun 10; 11():397-413. PubMed ID: 15988409
    [Abstract] [Full Text] [Related]

  • 7. Pathological changes in the vitreoretinal junction 1: epiretinal membrane formation.
    Snead DR, James S, Snead MP.
    Eye (Lond); 2008 Oct 10; 22(10):1310-7. PubMed ID: 18344963
    [Abstract] [Full Text] [Related]

  • 8. A new model of proliferative vitreoretinopathy.
    Frenzel EM, Neely KA, Walsh AW, Cameron JD, Gregerson DS.
    Invest Ophthalmol Vis Sci; 1998 Oct 10; 39(11):2157-64. PubMed ID: 9761295
    [Abstract] [Full Text] [Related]

  • 9. Apoptosis in proliferative vitreoretinal disorders: possible involvement of TGF-beta-induced RPE cell apoptosis.
    Esser P, Heimann K, Bartz-schmidt KU, Fontana A, Schraermeyer U, Thumann G, Weller M.
    Exp Eye Res; 1997 Sep 10; 65(3):365-78. PubMed ID: 9299173
    [Abstract] [Full Text] [Related]

  • 10. [Immunomorphological study of the vitreous body and subretinal fluid in vitreoretinal proliferation].
    Baudouin C, Brignole F, Bayle J, Fredj-Reygrobellet D, Lapalus P, Gastaud P.
    J Fr Ophtalmol; 1991 Sep 10; 14(3):147-52. PubMed ID: 1918821
    [Abstract] [Full Text] [Related]

  • 11. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy.
    Roldán-Pallarés M, Rollín R, Mediero A, Martínez-Montero JC, Fernández-Cruz A, Bravo-Llata C, Fernández-Durango R.
    Mol Vis; 2005 Jul 07; 11():461-71. PubMed ID: 16030497
    [Abstract] [Full Text] [Related]

  • 12. Class II histocompatibility antigen expression by cellular components of vitreous and subretinal fluid in proliferative vitreoretinopathy.
    Baudouin C, Brignole F, Bayle J, Fredj-Reygrobellet D, Lapalus P, Gastaud P.
    Invest Ophthalmol Vis Sci; 1991 Jun 07; 32(7):2065-72. PubMed ID: 2055699
    [Abstract] [Full Text] [Related]

  • 13. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery.
    Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ.
    Am J Ophthalmol; 2004 Jun 07; 137(6):1105-15. PubMed ID: 15183797
    [Abstract] [Full Text] [Related]

  • 14. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR.
    Liou GI, Pakalnis VA, Matragoon S, Samuel S, Behzadian MA, Baker J, Khalil IE, Roon P, Caldwell RB, Hunt RC, Marcus DM.
    Mol Vis; 2002 Dec 20; 8():494-501. PubMed ID: 12500176
    [Abstract] [Full Text] [Related]

  • 15. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy.
    Mandava N, Blackburn P, Paul DB, Wilson MW, Read SB, Alspaugh E, Tritz R, Barber JR, Robbins JM, Kruse CA.
    Invest Ophthalmol Vis Sci; 2002 Oct 20; 43(10):3338-48. PubMed ID: 12356843
    [Abstract] [Full Text] [Related]

  • 16. Soluble TNF receptors in vitreoretinal proliferative disease.
    Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH.
    Invest Ophthalmol Vis Sci; 2001 Jun 20; 42(7):1586-91. PubMed ID: 11381065
    [Abstract] [Full Text] [Related]

  • 17. [Recurrent vitreoretinal membranes in intravitreal silicon oil tamponade. Morphologic and immunohistochemical studies].
    Heidenkummer HP, Messmer EM, Kampik A.
    Ophthalmologe; 1996 Apr 20; 93(2):121-5. PubMed ID: 8652975
    [Abstract] [Full Text] [Related]

  • 18. [Pathomorphology of vitreoretinal proliferative membranes: review].
    Roshkius VP, Boiko EV.
    Georgian Med News; 2009 Oct 20; (175):20-2. PubMed ID: 19893117
    [Abstract] [Full Text] [Related]

  • 19. [Immunohistochemical study on vitrectomy specimens of proliferative retinal diseases].
    Cao J, Wu L, Zhang H.
    Zhonghua Yan Ke Za Zhi; 1997 Jul 20; 33(4):264-7. PubMed ID: 10451957
    [Abstract] [Full Text] [Related]

  • 20. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study.
    Kon CH, Occleston NL, Aylward GW, Khaw PT.
    Invest Ophthalmol Vis Sci; 1999 Mar 20; 40(3):705-12. PubMed ID: 10067974
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.